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Introduction
Pancreatic cancer is one of the most dismal types of can-
cer, with a 5- year survival rate of only 5–7% [1, 2]. These 
low survival rates reflect an advanced stage at diagnosis 
in the vast majority of patients: at least half of patients 
already have metastatic disease at time of diagnosis [3, 
4]. Median survival of unselected patients with metastatic 
disease is only 2–3 months [3–5].
Pancreatic cancer is predominantly a disease of the 
elderly [2, 6], at least half of all patients are over 70 years 
of age and more than one- fifth is older than 80 years 
[6, 7]. Unfortunately, elderly patients are underrepresented 
in clinical trials. For example, the phase III study which 
showed that FOLFIRINOX (oxaliplatin, irinotecan, fluo-
rouracil, and leucovorin) significantly improved survival 
compared with gemcitabine monotherapy (median survival 
11.1 vs. 6.8 months, respectively) excluded patients over 
75 years of age [8]. The phase III study on the combina-
tion of gemcitabine and nab- paclitaxel included patients 
until 88 years of age (median survival 8.5 months vs. 
6.7 months in patients with gemcitabine- alone), but the 
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Abstract
Despite an aging population and underrepresentation of elderly patients in clini-
cal trials, studies on elderly patients with metastatic pancreatic cancer are scarce. 
This study investigated the use of chemotherapy and survival in elderly patients 
with metastatic pancreatic cancer. From the Netherlands Cancer Registry, all 
9407 patients diagnosed with primary metastatic pancreatic adenocarcinoma in 
2005–2013 were selected to investigate chemotherapy use and overall survival 
(OS), using Kaplan–Meier and Cox proportional hazard regression analyses. 
Over time, chemotherapy use increased in all age groups (<70 years: from 26 
to 43%, 70–74 years: 14 to 25%, 75–79 years: 5 to 13%, all P < 0.001, and 
≥80 years: 2 to 3% P = 0.56). Median age of 2,180 patients who received 
chemotherapy was 63 years (range 21–86 years, 1.6% was ≥80 years). In 
chemotherapy- treated patients, with rising age (<70, 70–74, 75–79, ≥80 years), 
microscopic tumor verification occurred less frequently (91- 88- 87- 77%, respec-
tively, P = 0.009) and OS diminished (median 25- 26- 19- 16 weeks, P = 0.003). 
After adjustment for confounding factors, worse survival of treated patients 
≥75 years persisted. Despite limited chemotherapy use in elderly age, suggestive 
of strong selection, elderly patients (≥75 years) who received chemotherapy for 
metastatic pancreatic cancer exhibited a worse survival compared to younger 
patients receiving chemotherapy.
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median age of 63 years suggests that few patients were 
older than 75 years [9].
Population- based studies have shown that in the past 
decades the administration of palliative chemotherapy 
steeply increased in patients with metastatic pancreatic 
cancer [3, 10]. Whether the increased use of chemotherapy 
also applies to elderly patients, is unknown. Furthermore, 
some specialized institutions have reported acceptable safety 
and efficacy of chemotherapy in selected elderly patients 
with metastatic pancreatic cancer, with survival comparable 
with younger patients [11–13]. However, in these reports 
a direct comparison with younger patients (<75 years) 
was not performed [11, 12] or a single age cut- off (<70, 
≥70 years) was used [13] which may mask variation within 
the older age group. To the best of our knowledge, no 
population- based studies have been published which com-
pare survival after chemotherapy according to age.
Therefore, the purpose of this nationwide study is to 
examine the use of chemotherapy and its impact on overall 
survival in elderly patients with metastatic pancreatic can-
cer, using multiple age groups.
Methods
Netherlands cancer registry
In the Netherlands, a country with approximately 16.8 
million inhabitants, all newly diagnosed malignancies are 
recorded in the nationwide Netherlands Cancer Registry 
(NCR). Besides notification by the automated pathological 
archive (PALGA), the National Registry of Hospital 
Discharge Diagnoses is used. Subsequently, trained regis-
trars collect information on patient, tumor and primary 
treatment from the medical records in all Dutch hospitals. 
The International Classification of Diseases for Oncology 
(ICD- O- 3) is used for coding of morphology and tumor 
locations [14]. Histologically confirmed malignancies are 
staged according to the Tumor- Node- Metastasis (TNM) 
staging classification [15]. In patients without microscopi-
cally verified diagnosis a summary stage is recorded (Extent 
of Disease, EoD). Data quality is high and completeness 
is estimated to be at least 95%. Follow- up for all patients 
is obtained by routinely linking the NCR to the Municipal 
Personal Records Database (BRP). The BRP contains 
information on the vital status of all Dutch inhabitants 
(dead or alive, date of death or emigration). The NCR 
Review Board approved the study.
Patients
For this study, from the NCR all patients were selected 
who were diagnosed with primary invasive pancreatic 
(ductal) adenocarcinoma in the period 2005–2013 
(ICD- O- 3 C25, morphology codes 8010, 8012, 8020, 8140, 
8141, 8260, 8310, 8440, 8470, 8480, 8481, 8490, 8500, 
8560, or a nonmicroscopic verified invasive neoplasm of 
the pancreas suspected for adenocarcinoma). Patients 
diagnosed at autopsy, younger than 18 years or residing 
abroad were excluded. TNM and EoD staging information 
were combined to select patients with metastatic disease 
at diagnosis (53% of patients).
To investigate a possible age gradient or age cut- off 
point, patients were divided into four age groups: <70 years, 
70–74 years, 75–79 years and ≥80 years of age. Due to 
the nature of the NCR, information on prior primary 
malignancies was available in all patients. Additionally, a 
slightly modified version of the Charlson classification was 
recorded region- wide within 1–2 out of nine cancer regions 
(18% of all patients). Serious comorbid conditions included 
chronic obstructive pulmonary diseases, cardiovascular 
diseases, cerebrovascular diseases, digestive tract diseases, 
diabetes mellitus and other serious diseases. The number 
of comorbidities were categorized in three groups (0, 1, 
≥2). Furthermore, data on socioeconomic status (SES) 
were used [16]. SES was based on reference data from 
The Netherlands Institute for Social Research. Scores on 
social deprivation were derived from income, education 
and occupation per 4- digit postal code, and were broken 
into three SES- categories (high: 1st–3rd, intermediate: 
4th–7th, low: 8th–10th deciles). Registered treatment after 
diagnosis included the cancer treatment modalities as 
mentioned in the treatment plan and provided to the 
patient (i.c. resection, radiotherapy, chemotherapy). Time 
intervals between date of diagnosis and date of initiating 
chemotherapy were calculated to explore possible delay.
Survival time was calculated from the date of diagnosis 
to the date of death or 1 January 2015, whichever came 
first. To reduce the influence of survivor treatment selec-
tion bias in analysis of survival of patients with versus 
without chemotherapy [17], only patients were selected 
who survived at least 30–days after diagnosis (conditional 
survival). In addition to information about delay of start-
ing chemotherapy, survival time from the starting date 
of chemotherapy was calculated.
Statistical analysis
In each age group of patients with metastatic pancreatic 
cancer, Chi square tests for trend were performed to 
assess the administration of chemotherapy in consecutive 
3- year periods (2005–2007, 2008–2010, 2011–2013). A 
two- sided P < 0.05 was considered statistically significant. 
In patients receiving palliative chemotherapy, Chi- square 
tests were also used to compare patient, tumor and 
treatment characteristics between age groups. To compare 
time intervals between groups of patients, nonparametric 
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Kruskal–Wallis tests were used. Univariable and multi-
variable logistic regression analyses were performed to 
investigate the association of patient and tumor char-
acteristics with the administration of chemotherapy. 
Kaplan–Meier analyses with log rank tests were used 
(1) to evaluate overall survival of all patients with meta-
static disease and (2) to compare overall and conditional 
survival of chemotherapy- treated and untreated patients 
within the different age groups. In patients receiving 
chemotherapy, univariable and multivariable Cox pro-
portional hazard regression analyses were performed to 
evaluate predictors for a worse survival, using survival 
time calculated from (1) date of diagnosis and from 
(2) starting chemotherapy. In multivariable models, a 
backward stepwise elimination procedure was used with 
a P > 0.10 in likelihood ratio tests for removal of vari-
ables. Missing values were included as separate categories 
or dummy variables. In sensitivity analyses using region- 
wide data only, the additional influence of the number 
and type of comorbid conditions was investigated (in 
addition to the predictors derived from the multivari-
able models in the total population). All analyses were 
performed using STATA/SE (version 13.0; STATA Corp., 
College Station, TX).
Results
Patients with metastatic pancreatic cancer
Of 9,407 patients diagnosed with metastatic pancreatic 
cancer in the period 2005–2013, 32% was 75 years or 
older. Twenty- three per cent of all patients received pal-
liative chemotherapy. Over time, the administration of 
palliative chemotherapy more than doubled from 13% in 
2005 to 30% in 2013 (P < 0.001). Although treatment 
with chemotherapy was far less common in elderly patients, 
an increased use of chemotherapy was found in all age 
groups (Fig. 1). In consecutive 3- year periods, from 26% 
to 43% of patients under age 70 years received chemo-
therapy, from 14% to 25% of patients aged 70–74 years 
and from 5% to 13% of patients aged 75–79 years (all 
P < 0.001). Over age 80 years very few patients were 
treated with chemotherapy and the very small increase 
of 2–3% was not statistically significant (P = 0.56). Besides 
elderly patients (≥70 years) and patients diagnosed in 
earlier years, also patients living in low SES neighbor-
hoods, without tumor verification, with tumors located 
in the pancreatic head and patients with multiple metastatic 
sites independently had a lower probability of receiving 
chemotherapy (Table 1), In addition, the accumulation 
of comorbid conditions showed a stronger association with 
not receiving chemotherapy than specific comorbid 
conditions.
Median overall survival (OS) of patients with metastatic 
pancreatic cancer was 9.5 weeks (with rising age of 
patients [<70, 70–74, 75–79, ≥80 years]: 13- 10- 8- 5 weeks, 
respectively, P < 0.001), and OS was 7 weeks in untreated 
patients versus 25 weeks (5.7 months) in patients who 
received chemotherapy (P < 0.001). As many as 26% 
of all patients died within 30 days after diagnosis (with 
rising age: 19- 26- 32- 43%, P < 0.001). In patients who 
survived 30 days, Chemotherapy- treated patients under 
75 years survived longer compared to untreated patients 
(conditional survival [CS] <70 years: median 26 vs. 
12 weeks, 70–74 years: 27 vs. 11 weeks, both P < 0.001), 
but the survival difference was smaller in patients over 
75 years of age (75–79 years: median 20 vs. 11 weeks, 
P < 0.001, ≥80 years: 16 vs. 10 weeks, P = 0.02, Fig. 2).
Patients receiving systemic chemotherapy
Median age of 2,180 patients who received palliative 
chemotherapy for metastatic pancreatic cancer was 63 years 
(range, 21–86 years) and increased from 62 years in 
2005–2007 to 64 years in 2011–2013. Eight per cent of 
treated patients were 75 years or older and only few 
patients were over 80 years of age (n = 35, 1.6%). With 
rising age (<70, 70–74, 75–79, ≥80 years), the prevalence 
of a prior cancer diagnosis and the number of comorbid 
conditions increased (both P < 0.001), particularly cardiac 
and vascular diseases (P < 0.001 and P = 0.001, respec-
tively, Table 2). Furthermore, older patients less often 
had microscopic verification of the current cancer (91%, 
88%, 87%, 77%, respectively, P = 0.009), although they 
all received chemotherapy.
The date of initiation of chemotherapy was available 
in 77% of patients and characteristics of these patients 
did not differ from the total group of patients (data not 
shown). Median time- to- chemotherapy was 25 days ([p25- 
p75] 15–43 days) and elderly patients started chemotherapy 
sooner after diagnosis (Table 2), as well as patients with 
nonhead tumors (head: median 32 days, nonhead: 21, 
Figure 1. Administration of chemotherapy to patients diagnosed with 
metastatic pancreatic cancer in consecutive time periods in the 
Netherlands, by age group.
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P < 0.001) and patients with at least two metastatic sites 
(1: median 27 days, ≥2: 22, P < 0.001).
With rising age (<70, 70–74, 75–79, ≥80 years), median 
OS of treated patients decreased: 25, 26, 19, and 16 weeks, 
respectively, (P = 0.003). In univariable survival analysis 
of patients who received chemotherapy, a higher probability 
of worse OS was found in patients over 75 years of age, 
patients treated in earlier years of our study period, with-
out microscopic tumor verification, with nonhead cancer, 
and in patients with multiple metastatic sites (Table 3). 
In the multivariable Cox proportional hazard model, all 
these characteristics were independently associated with 
a poor OS. Compared with chemotherapy- treated patients 
younger than 70 years of age, patients over 75 years of 
Table 1. Characteristics of patients with primary pancreatic adenocarcinoma and synchronous distant metastases in the period 2005- 2013 in the 
Netherlands, by administration of chemotherapy (CT) and logistic regression analyses predicting administration of chemotherapy.
Patients CT Univariable analysis Multivariable analysis
N = 9407 (%) % OR (95% CI) P - value OR (95% CI) P- value
Age <0.001 <0.001
<70 years 4729 (50) 35 1.00 1.00
70–74 years 1623 (17) 20 0.46 (0.41–0.53) 0.49 (0.43–0.57)
75–79 years 1437 (15) 9.9 0.20 (0.17–0.24) 0.23 (0.19–0.28)
≥80 years 1618 (17) 2.2 0.04 (0.03–0.06) 0.06 (0.04–0.09)
Year of diagnosis 9407 (100) 23 1.12 (1.10–1.15) <0.001 1.12 (1.10–1.15) <0.001
Gender
Male 4852 (52) 25 1.00 0.001
Female 4555 (48) 22 0.85 (0.77–0.93)
History of cancer
No 8104 (86) 24 1.00 <0.001 1.00 0.07
Yes 1303 (14) 18 0.70 (0.60–0.81) 0.86 (0.73–1.01)
SES
High 2,839 (30) 26 1.00 <0.001 1.00 0.006
Intermediate 3,736 (40) 23 0.89 (0.80–1.00) 0.95 (0.84–1.07)
Low 2,832 (30) 21 0.76 (0.67–0.86) 0.81 (0.71–0.93)
Tumor verification <0.001 <0.001
Verified 6,486 (69) 30 1.00 1.00
No verification 2,921 (31) 7 0.18 (0.15–0.21) 0.29 (0.25–0.34)
Primary tumor <0.001
Head of 
pancreas
4567 (49) 21 1.00 1.00
Body or tail 3254 (35) 27 1.42 (1.28–1.57) 1.33 (1.19–1.49) <0.001
Overlapping/NOS 1586 (17) 20 0.95 (0.83–1.10) 0.98 (0.84–1.14)
Metastatic site
1 6283 (67) 24 1.00 <0.001 1.00 <0.001
≥2 2808 (30) 23 0.95 (0.86–1.06) 0.79 (0.70–0.89)
Unknown 316 (3.4) 12 0.44 (0.31–0.62) 0.62 (0.43–0.90)
Sensitivity analysis1
Comorbid c. (n = 1697) <0.001 2 0.06
0 420 (25) 36 1.00 1.00
1 466 (27) 26 0.63 (0.47–0.83) 0.78 (0.57–1.07)
≥2 590 (35) 19 0.40 (0.30–0.54) 0.67 (0.48–0.94)
Unknown 221 (13) 16 0.34 (0.23–0.52) -
Comorbid c. (% yes) (yes vs. no) 2
Diabetes 394 (27) 23 0.82 (0.63–1.08) 0.16
Cardiac 353 (24) 15 0.43 (0.32–0.60) <0.001
Vascular 271 (18) 17 0.51 (0.36–0.72) <0.001 0.69 (0.47–1.04) 0.07
Pulmonary 170 (12) 18 0.58 (0.38–0.87) 0.009
Hypertension 450 (31) 23 0.79 (0.61–1.02) 0.07
Digestive tract 151 (10) 28 1.11 (0.76–1.61) 0.60
CT, chemotherapy; Comorbid c., Comorbid conditions; SES, socioeconomic status; NOS, not otherwise specified; OR, odds ratio; CI, Confidence 
Interval.
 1Region- wide data only n = 1697 (18% of all patients). Multivariable model adjusted for variables included in model using nationwide data (age, year 
of diagnosis, history of cancer, SES, tumor verification, primary tumor and number of metastatic sites).
2Excluding n = 221 patients with unknown comorbid conditions because of collinearity.
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age who received chemotherapy showed a worse OS (Hazard 
Ratio [HR] (75–79 vs. <70) = 1.21, 95% CI 1.02–1.44; 
HR (≥80 vs. <70) = 1.48, 95% CI: 1.06–2.07), but the 
intermediate age group did not (HR [70–74 vs. <70]=0.92, 
95% CI: 0.81–1.03, P = 0.16). In sensitivity analysis, the 
number and type of comorbid conditions of treated patients 
seemed not significantly associated with a poor OS (bor-
derline: pulmonary diseases: adjusted HR = 1.38, 95% 
CI: 0.94–2.01, P = 0.10).
Using survival time calculated from the starting date of 
chemotherapy, median OS of treated patients was 20 weeks. 
With rising age (<70, 70–74, 75–79, ≥80 years), median 
survival was 20, 22, 16 and 13 weeks, respectively, (P = 0.006, 
Fig. 3). No survival difference was found according to 
tumor location (univariable HR [body/tail vs head]=1.07, 
95% CI: 0.96–1.19, P = 0.43), but other above- mentioned 
prognostic characteristics were independently associated with 
a worse OS (age: HR [70–74 vs <70] = 0.93, 95% CI: 
0.81–1.07, HR [75–79 vs <70] = 1.24, 95% CI: 1.02–1.51, 
HR [≥80 vs. <70] = 1.68, 95% CI 1.13–2.50).
Discussion
To our knowledge, this is the first nationwide study of 
patients with metastatic pancreatic cancer that investigated 
chemotherapy use and survival in multiple elderly age 
groups. The administration of palliative systemic therapy 
doubled between 2005 and 2013 in all age groups. 
Compared with younger patients receiving chemotherapy, 
treated patients over 75 years of age less often underwent 
microscopic tumor verification of cancer and showed a 
worse overall survival.
In consistent with previous population- based reports, 
overall survival of patients with primary metastatic 
pancreatic cancer in our study was only 2–3 months [4, 
5, 18]. Our nationwide study also confirmed a recent 
regional report from the Netherlands that the administra-
tion of palliative chemotherapy has increased rapidly in 
the past decade [3]. Chemotherapy prescription in the 
Netherlands, however, (overall 23%, patients surviving 
30 days 31%), seemed relatively low compared with 
population- based studies from the USA and France (42–
54%) [10, 19–21]. Although no information on the type 
of chemotherapy was available in our study, it is plausible 
that gemcitabine- based therapies were prescribed to the 
vast majority of patients in the selected time period [20–22]. 
Treatment preference for gemcitabine was mainly based 
on its favorable clinical benefit response (pain, performance 
status, weight) and toxicity profile compared to 
5- fluorouracil (5- FU) [23, 24]. Only recently, the studies 
by Conroy et al. on FOLFIRINOX (oxaliplatin, irinotecan, 
fluorouracil, and leucovorin) [8] and Von Hoff et al. on 
the combination of gemcitabine and nab- paclitaxel 
(MPACT- trial) [9] opened new treatment perspectives 
[25–27]. However, despite a good performance status of 
included patients, prolonged survival in these studies went 
along with an increased risk of side effects. Possibly, modi-
fied FOLFIRINOX or gemcitabine with nab- paclitaxel 
treatment may be beneficial to older patients or patients 
with a less favourable performance status [28].
Similar to other reports [3, 20, 21], chemotherapy use 
in the current study was far less likely in elderly patients 
with metastatic pancreatic cancer. Although the number 
of octogenarians receiving chemotherapy hardly increased, 
in the course of our study the age of patients who received 
palliative chemotherapy rose. In patients aged 70–74 years 
who received chemotherapy, tumor verification rate, tim-
ing of chemotherapy, early mortality and overall survival 
Figure 2. Median overall survival and conditional overall survival with 95% confidence interval of patients who received palliative chemotherapy (CT) 
for metastatic pancreatic cancer compared with untreated patients (no- CT), by age group.
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in our study were very similar to that of treated patients 
younger than 70 years. However, although very few and 
therefore highly selected elderly patients over 75 years of 
age were treated with palliative chemotherapy, a poor 
survival after chemotherapy was particularly found in this 
elderly age groups. Survival of treated elderly patients in 
Table 2. Characteristics of patients who received palliative chemotherapy (CT) for metastatic pancreatic cancer in the period 2005–2013 in the 
Netherlands, by age group.
All patients <70 years 70–74 years 75–79 years ≥80 years Chi2  
P–valueN = 2180% N = 1674% N = 329% N = 142% N = 35%
Patient
Gender
Male 1194 (55) 56 51 54 57 0.49
Female 986 (45) 44 49 46 43
Socioeconomic status (SES)
High 724 (33) 33 34 29 40
Intermediate 874 (40) 40 38 42 46 0.56
Low 582 (27) 27 28 29 14
History of cancer
No 1944 (89) 91 85 77 77 <0.001
Yes 236 (11) 8.7 15 23 23
Comorbid c.1 (n = 420) (n = 325) (n = 64) (n = 27) (n = 4) <0.001
0 152 (36) 42 17 22 0
1 122 (29) 30 25 26 50
2+ 110 (26) 20 52 37 25
Unknown 36 (8.6) 8.3 6.3 15 25
Comorbid c. 
(%yes)1
(n = 384)2 (n = 298)2 (n = 60)2 (n = 23)2 (n = 3)2
Diabetes 92 (24) 21 35 30 0 0.09
Cardiac disease 54 (14) 9.7 28 26 67 <0.001
Vascular disease 45 (12) 8.4 25 17 33 0.001
Pulmonary disease 30 (7.8) 7.1 13 4.4 0 0.33
Hypertension 103 (27) 24 40 26 33 0.09
Digestive tract 
disease
42 (11) 9.7 10 26 33 0.06
Tumor
Tumor verification 0.009
Verified 1968 (90) 91 88 87 77
No verification 212 (9.7) 8.8 12 13 23
Primary tumor 0.27
Head of pancreas 964 (44) 44 48 44 34
Body or tail 894 (41) 42 36 39 57
Other or 
overlapping
322 (15) 15 16 17 8.6
Number of metastatic sites
1 1497 (69) 69 69 63 69 0.51
≥2 645 (30) 29 28 37 31
Unknown 38 (1.7) 1.8 2.1 0.7 0
Time interval to CT
Median 
[p25–p75] in 
days3 
25 [15–42] 26 [15–43] 26 [16–48] 21 [13–33] 18 [13–34] 0.007
≥6 weeks3 443 (26) 27 29 17 12 0.03
Mortality of starting CT
30–day mortality3 141 (8.4) 8.0 8.5 10.0 20.0 0.17
90–day mortality3 541 (32) 31 31 44 48 0.02
Comorbid c., Comorbid conditions; SES, socioeconomic status; NOS, not otherwise specified; N, number of patients.
1Region–wide data only n = 420 (18% of all patients).
2excluding patients with unknown comorbid conditions.
3If date of initiating chemotherapy is available n = 1676 (77% of all patients).
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our nationwide study (≥75 years: median 4.0 months) 
was strikingly worse than the median of 7–8 months in 
previous mono- institutional cohorts of patients over 
75 years of age [11, 12]. Our observations are likely related 
to the nationwide character of our study with a less selec-
tive cohort of elderly patients. Furthermore, additional 
analyses of the MPACT- study data showed that older age 
(defined as ≥65 years) was an independent predictor for 
both worse overall and progression- free survival [29]. 
Unlike older age, in our study comorbid conditions seemed 
not strongly associated with a worse overall survival of 
treated patients. Possibly, a loss of ‘functional reserve’ 
due to the process of aging may add to a worse survival 
of elderly patients, resulting in increased toxicity or reduced 
Table 3. Crude median overall survival and univariable and multivariable Cox proportional hazards regression analyses predicting survival of patients 
who received palliative chemotherapy for metastatic pancreatic cancer in the period 2005–2013 in the Netherlands.
Characteristics MS months
Univariable analysis Multivarivable analysis
HR (95% CI) P - value HR (95% CI) P - value
Age 0.003 0.008
<70 years 5.8 Ref Ref
70–74 years 6.0 0.93 (0.83–1.05) 0.92 (0.81–1.03)
75–79 years 4.3 1.25 (1.05–1.48) 1.21 (1.02–1.44)
≥80 years 3.7 1.58 (1.13–2.21) 1.48 (1.06–2.07)
Year of diagnosis 5.7 0.98 (0.96–1.00) 0.05 0.98 (0.96–1.00) 0.03
Gender 0.30
Male 5.5 Ref 
Female 6.2 0.96 (0.88–1.04)
History of cancer 0.85
No 5.7 Ref 
Yes 6.0 0.99 (0.86–1.13)
SES
High 5.8 Ref 0.27
Medium 5.5 1.05 (0.95–1.16)
Low 6.0 1.09 (0.98–1.22)
Tumor verification 0.02 0.007
Verification 5.8 Ref Ref
No verification 4.9 1.19 (1.03–1.37) 1.22 (1.05–1.41)
Primary tumor <0.001 0.002
Head 6.2 Ref Ref 
Body or tail 5.4 1.21 (1.11–1.33) 1.17 (1.07–1.29)
Overlapping/NOS 5.7 1.17 (1.03–1.33) 1.17 (1.03–1.33)
Metastatic sites <0.001 <0.001
1 6.2 Ref Ref 
≥2 5.0 1.38 (1.25–1.51) 1.36 (1.23–1.49)
Unknown 5.6 1.13 (0.82–1.56) 1.07 (0.76–1.49)
Sensitivity analysis1
Comorbid c. 0.06 2
0 5.8 Ref
1 6.0 0.97 (0.76–1.23)
≥2 5.4 1.18 (0.96–1.51)
Unknown 6.3 0.71 (0.49–1.03)
Comorbid c. (if yes) (yes vs. no) 2
Diabetes 5.8 1.10 (0.87–1.40) 0.42
Cardiac 5.2 0.97 (0.72–1.30) 0.84
Vascular 4.8 1.02 (0.74–1.40) 0.90
Pulmonary 5.4 1.40 (0.96–2.03) 0.10 1.38 (0.94–2.01) 0.10
Hypertension 5.8 1.16 (0.92–1.46) 0.22
Digestive tract 7.1 0.84 (0.61–1.16) 0.29
Survival calculated from date of diagnosis (100% of patients).
MS, median survival; Comorbid c., Comorbid conditions; SES, socioeconomic status; NOS, not otherwise specified; HR, hazard ratio; CI, Confidence 
Interval.
1Region–wide data only n = 420 (18% of all patients). Multivariable model adjusted for variables included in model using nationwide data (age, year 
of diagnosis, tumor verification, primary tumor, and number of metastatic sites).
2Excluding n = 36 patients with unknown comorbid conditions because of collinearity.
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dose adherence and consequently reduced treatment effi-
cacy and survival. Therefore, geriatric characteristics and 
co- morbid features predictive of treatment intolerance 
should be better defined.
Overall, survival of the total group of patients who 
received palliative chemotherapy in our study was similar 
to other observational studies (median 5.7 vs. 
5–6.4 months) [13, 20, 22]. Although as many as 32% 
of patients in our study died within 90 days of starting 
chemotherapy, this may reflect the treatment goal directed 
at symptom management and the progressive character 
of pancreatic cancer. Generally, chemotherapy use in the 
last weeks of life is considered undesirable end- of- life care 
[30]. Particularly in pancreatic cancer patients with their 
already poor prognosis, palliative chemotherapy may jeop-
ardize quality of end- of- life care and yield a limited cost- 
effectiveness [31]. Therefore, a better selection of patients 
with pancreatic cancer who may benefit from available 
palliative chemotherapies is clearly needed.
Most previous observational studies only included 
patients with microscopically confirmed pancreatic cancer 
[5, 11, 13, 21, 22, 32]. Although pathologic confirmation 
of pancreatic cancer prior to chemotherapy is strongly 
recommended [27, 33], one in ten of treated patients in 
our study started chemotherapy without prior microscopic 
tumor verification. Especially in elderly patients, micro-
scopic verification was often omitted. Although in selected 
patients, a suspected mass on computer tomography (CT), 
elevated serum marker CA19- 9 and cancer- specific symp-
toms may result in a high specificity for pancreatic cancer 
[34], misdiagnosis cannot be ruled out [35, 36].
Our population- based study also revealed that especially 
patients with pancreatic head tumors started palliative 
chemotherapy several weeks after diagnosis (median, 
4–5 weeks). Many patients with pancreatic head tumors 
undergo stent placement to solve bile duct obstruction 
[37]. Other patients must recover from explorative surgical 
procedures [38–40]. Stent dysfunction and surgical mor-
bidity may have delayed or precluded chemotherapy in 
a number of patients with metastatic disease. Indeed, 
patients with pancreatic head cancer in our study less 
likely received palliative chemotherapy (21%, vs. 27% in 
patients with body or tail disease).
Important limitations in this population- based study 
concern the availability of data. Firstly, completeness 
of pancreatic cancer diagnoses in the NCR was ques-
tioned recently [41]. Although chemotherapy use in 
elderly patients and survival of untreated patients might 
slightly be overestimated, analyses of treated patients 
are expected to be highly accurate. Secondly, the NCR 
does not contain nationwide data on comorbid condi-
tions and performance status of patients. However, 
patients who received palliative chemotherapy for pan-
creatic cancer may already have a relatively favorable 
performance status and available (region- wide) comor-
bidity data did not show significant associations with 
a poor survival. Furthermore, this nationwide population- 
wide study reflects real- world treatment and survival 
patterns and also included patients without microscopic 
confirmation of cancer and patients who underwent 
pancreatic resection (0.7%). Excluding these patient 
groups did not alter our results. Thirdly, although con-
ditional survival analysis has reduced survivor treatment 
bias (immortal time bias), treatment choice was not at 
random (treatment selection bias) [17]. Therefore, the 
observed differences between treated and untreated 
patients are likely an overestimation of true survival 
differences. Finally, starting dates of chemotherapy were 
available in only three quarters of patients. However, 
patients were representative for the total patient popula-
tion and the available data revealed important informa-
tion about the treatment process. The recently initiated 
Dutch nationwide PAncreatic CAncer Project (PACAP), 
which combines data from the NCR with the Dutch 
Pancreatic Cancer Audit and Dutch Pancreatic Biobank, 
is expected to provide more detailed information on 
systemic treatment in patients with pancreatic cancer, 
such as type and amount of chemotherapy [42].
Conclusions
Despite a limited chemotherapy use in elderly patients, 
suggestive of strong selection, especially patients over 
75 years of age who received chemotherapy showed a 
poor survival. Improved definition of the geriatric char-
acteristics and co- morbid features predictive of treatment 
intolerance is necessary to optimize selection of elderly 
Figure 3. Crude overall survival of patients who received palliative 
chemotherapy for metastatic pancreatic cancer, by age group. Survival 
calculated from date of starting chemotherapy (77% of patients). Log 
rank test P = 0.006.
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patients for palliative chemotherapy. In addition, appro-
priate chemotherapy regimens are required that are better 
tolerated by elderly patients.
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